Project Grant R03TR005085
Award Date
6/16/25
Completion Date
6/15/26
Dollars Obligated
$156K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,323,125.00 in funding to the University of California, Los Angeles (UCLA) to investigate the role of the RNA-binding protein ZFP36 in the pathogenesis of pulmonary arterial hypertension (PAH). The research aims to use large-scale transcriptomic data and computational biology to identify the targets of ZFP36 and characterize their...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the role of the epigenetic regulator SIN3A in regulating BMPR2 and pulmonary endothelial cell dysfunction in pulmonary arterial hypertension (PAH). The Icahn School of Medicine at Mount Sinai, the awardee, will conduct sophisticated functional validation assays, explore the SIN3A/FOXK2 interplay, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $760,708 to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension. The research aims to: Investigate the impact of the APA regulator CPSF6 depletion on the 3' UTR landscape and profibrotic gene expression in RV failure. Uncover the mechanism underlying CPSF6...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) provides $1,617,792.00 to The Leland Stanford Junior University to conduct research on the role of the carboxylesterase 1 (CES1) enzyme in the development and progression of pulmonary arterial hypertension (PAH). The research aims to determine how loss of CES1 leads to metabolic reprogramming, lipotoxicity, and oxidative stress in...
The National Heart Lung and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR...
The federal Project Grant award R01HL176673, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the molecular mechanisms by which the protein factor Response Gene to Complement 32 (RGC-32) regulates endothelial-mesenchymal transition (EndoMT) of pulmonary artery endothelial cells and its role in the development of pulmonary arterial hypertension (PAH). The $658,885 award, with a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $244,589 to support research on the role of the protein VPS34 in the development and progression of pulmonary arterial hypertension (PAH). The primary research aims are to: 1) examine the regulation and activation of VPS34 in the pulmonary vasculature of PAH patients, 2) determine the impact of VPS34 on the proliferation and...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $498,000.00 to fund research at National Jewish Health, a non-profit hospital and research center in Denver, Colorado. The primary objective is to support the development of an independent research scientist, Dr. Woodcock, through active mentorship, training, and a research program focused on the role of RNA editing in...
This $5,715,866 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies to substantially reduce the burden of pulmonary fibrosis (PF). The 5-year program will focus on investigating the early, pre-symptomatic progression of familial pulmonary fibrosis (FPF) to identify critical mechanisms driving disease initiation and progression. Key activities include: Analyzing...